Edwards Lifesciences Corp

For the period ended Mar 31, 2026. Filed May 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 6, 2026

EW$104.01-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in millions, except per share information; unaudited)

	Three Months EndedMarch 31,
	2026	2025
Net sales	$1,648.6	$1,412.7
Cost of sales	362.6	301.6
Gross profit	1,286.0	1,111.1
Selling, general, and administrative expenses	522.2	465.7
Research and development expenses	263.3	254.6
Certain litigation expenses	37.1	10.9
Separation costs	—	4.2
Other operating income	(14.2)	(19.1)
Operating income, net	477.6	394.8
Interest income, net	(33.5)	(36.5)
Loss on impairment (Note 6)	123.6	—
Other non-operating income, net (Note7)	(71.5)	(2.6)
Income from continuing operations before provision for income taxes	459.0	433.9
Provision for income taxes	78.3	70.3
Net income from continuing operations	380.7	363.6
Loss from discontinued operations, net of tax	—	(7.2)
Net income	380.7	356.4
Less: Net loss attributable to noncontrolling interest	—	(1.6)
Net income attributable to Edwards Lifesciences Corporation	$380.7	$358.0
Share information (Note 14)
Earnings (loss) per share:
Basic
Continuing operations	$0.66	$0.62
Discontinued operations	$—	$(0.01)
Basic earnings per share	$0.66	$0.61
Diluted
Continuing operations	$0.66	$0.62
Discontinued operations	$—	$(0.01)
Diluted earnings per share	$0.66	$0.61
Weighted-average number of common shares outstanding:
Basic	579.2	586.9
Diluted	580.7	587.8

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.